Studies on Coumarin Anticoagulant Drugs: Initiation of Warfarin Therapy Without a Loading Dose

Thirty normal subjects were given a single loading dose of warfarin sodium, 1.5 mg/kg of body weight. The drug was metabolized slowly (mean biological half-life, 47 hr) and showed a prolonged biological effect (over 6 days). In two separate experiments no loading dose was given; instead, daily doses of 15 mg and 10 mg were administered to 15 of the subjects. The prothrombin complex responses were compared with those obtained in the same subjects after the large loading dose. The mean time in days to reach the therapeutic range (prothrombin complex activity<35% of normal) was 1.1 days with the dose of 1.5 mg/kg of body weight, 2.7 days with the dose of 15 mg/day, and 5.2 days with 10 mg/day. With all three methods the therapeutic range was reached soon after a level of warfarin of 2 mg/L plasma was attained.The rates of fall of the four vitamin K-dependent clotting factors (II, VII, IX, and X) with the large loading dose and with the daily dosage of 15 mg were compared in six of the subjects. With the loading dose, factor VII activity was less during the first 48 hr, but there was no other significant difference between the two methods of drug administration in the amount of reduction of any of the four factors.Since the role of factor VII in thrombogenesis is questioned, these results provide a rational basis for the induction of prophylactic anticoagulant therapy without large loading doses of warfarin. Avoidance of the customary loading dose should reduce the danger of hemorrhage, particularly in patients who are sensitive to the drug because of advanced age, sepsis, liver disease, congestive heart failure, or recent surgery or trauma.

[1]  R A O'REILLY,et al.  STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN. , 1963, The Journal of clinical investigation.

[2]  M. Hoag,et al.  Studies on the Coumarin Anticoagulant Drugs : The Assay of Warfarin and its Biologic Application , 1962, Thrombosis and Haemostasis.

[3]  L. Hyland ANTICOAGULANT THERAPY. , 1964, Minnesota medicine.

[4]  M. Weiner THE SIGNIFICANCE OF THE PHYSIOLOGIC DISPOSITION OF DRUGS IN ANTICOAGULANT THERAPY. , 1964, Seminars in hematology.

[5]  L. Kessel,et al.  PREVENTION OF VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN INJURED PATIENTS , 1962 .

[6]  P. Owren,et al.  The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. , 1951, Scandinavian journal of clinical and laboratory investigation.

[7]  E NELSON,et al.  Kinetics of drug absorption, distribution, metabolism, and excretion. , 1961, Journal of pharmaceutical sciences.

[8]  D. Deykin,et al.  Evidence for an antithrombotic effect of Dicumarol. , 1960, American Journal of Physiology.

[9]  C. Borchgrevink,et al.  THE HAEMOSTATIC MECHANISM IN PATIENTS WITH HAEMORRHAGIC DISEASES. A HISTOLOGICAL STUDY OF WOUNDS MADE FOR PRIMARY AND SECONDARY BLEEDING TIME TESTS. , 1964, Acta pathologica et microbiologica Scandinavica.

[10]  G. Eskeland Prevention of venous thrombosis and pulmonary embolism in injured patients. , 1962, Lancet.

[11]  S WESSLER,et al.  Thrombosis in the presence of vascular stasis. , 1962, The American journal of medicine.

[12]  E. Loeliger,et al.  Factor VII; its turnover rate and its possible role in thrombogenesis. , 1960, Thrombosis et diathesis haemorrhagica.

[13]  W. Harris,et al.  Anticoagulation for prevention of thromboembolism following fractures of the hip. , 1966, The New England journal of medicine.

[14]  H. Rowsell,et al.  Experimental hemostasis in normal dogs and dogs with congenital disorders of blood coagulation. , 1967, Blood.

[15]  F. Duckert,et al.  The Stuart-Prower Factor Assay and its Clinical Significance , 1958, Thrombosis and Haemostasis.

[16]  F. Marcus,et al.  Administration of Tritiated Digoxin with and without a Loading Dose: A Metabolic Study , 1966, Circulation.

[17]  R. Macfarlane An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical Amplifier , 1964, Nature.

[18]  S SEVITT,et al.  Prevention of venous thrombosis and pulmonary embolism in injured patients. A trial of anticoagulant prophylaxis with phenindione in middle-aged and elderly patients with fractured necks of femur. , 1959, Lancet.

[19]  van der Esch,et al.  Factor VII: its Turnover Rate and its Possible Role in Thrombogenesis , 1960, Thrombosis and Haemostasis.

[20]  E. Bowie,et al.  Disappearance Rates of Coagulation Factors: Transfusion Studies in Factor‐Deficient Patients , 1967, Transfusion.

[21]  Macfarlane Rg,et al.  AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER , 1964 .

[22]  E. Loeliger,et al.  Behaviour of Factors II, VII, IX, and X during Long-Term Treatment with Coumarin , 1963, Thrombosis and Haemostasis.